The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

Oncolytic immunotherapeutics (OIs) are viruses designed to preferentially replicate in and lyse cancer cells, thereby triggering antitumor immunity. Numerous oncolytic platforms are currently in clinical development. Here we review preclinical and clinical experience with Pexa-Vec (pexastimogene dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Breitbach, Caroline J, Bell, John C, Hwang, Tae-Ho, Kirn, David H, Burke, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918374/
https://www.ncbi.nlm.nih.gov/pubmed/27512667
http://dx.doi.org/10.2147/OV.S59640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918374/
https://www.ncbi.nlm.nih.gov/pubmed/27512667
http://dx.doi.org/10.2147/OV.S59640

Ejemplares similares